Trials / Completed
CompletedNCT01105247
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PCI-32765 | 420 mg daily or 840 mg daily |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2012-12-01
- Completion
- 2013-02-01
- First posted
- 2010-04-16
- Last updated
- 2014-03-31
- Results posted
- 2014-03-31
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01105247. Inclusion in this directory is not an endorsement.